Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT01447654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
Henning Bundgaard (from the registry)
Registry
  • NCT NCT01447654
Other papers using this trial's data
  • Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial The lancet. Diabetes & endocrinology, 2015-02 DOI, PubMed 25533774
  • Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial Heart (British Cardiac Society), 2016-02-15 DOI, PubMed 26661322

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01447654. Randomized; quadruple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
Acronym
INHERIT
Condition
Hypertrophic Cardiomyopathy
Intervention (Drug)
Losartan
Intervention (Drug)
Placebo
Lead sponsor
Henning Bundgaard (class: other)

Record details

Record id
cardio:ct-nct01447654
Content hash
0d1fe39af3fc1ee66eec444da905d827faed8ffc69831f71a9152889563a0394